Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of SNB-101, in Extensive Stage Small Cell Lung Cancer.

NCT07391813 is registered in ClinicalTrials.gov with SN BioScience as lead sponsor.

NCT NCT07391813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07391813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of SNB-101, in Extensive Stage Small Cell Lung Cancer.
Lead sponsor
SN BioScience
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 31, 2026
Completion date
December 31, 2028
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patient is not suitable for complete surgical resection with a cytologically or histologically confirmed small cell lung cancer(sclc)